These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38753112)

  • 1. Dalbavancin as suppressive therapy for implant-related infections: a case series with therapeutic drug monitoring and review of the literature.
    Lafon-Desmurs B; Gachet B; Hennart B; Valentin B; Roosen G; Degrendel M; Loiez C; Beltrand E; D'Elia P; Migaud H; Robineau O; Senneville E
    Eur J Clin Microbiol Infect Dis; 2024 Jul; 43(7):1475-1480. PubMed ID: 38753112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept.
    Cojutti PG; Rinaldi M; Gatti M; Tedeschi S; Viale P; Pea F
    Int J Antimicrob Agents; 2021 Nov; 58(5):106445. PubMed ID: 34614441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dalbavancin for treating prosthetic joint infections caused by Gram-positive bacteria: A proposal for a low dose strategy. A retrospective cohort study.
    Buzón Martín L; Mora Fernández M; Perales Ruiz JM; Ortega Lafont M; Álvarez Paredes L; Morán Rodríguez MA; Fernández Regueras M; Machín Morón MA; Mejías Lobón G
    Rev Esp Quimioter; 2019 Dec; 32(6):532-538. PubMed ID: 31642637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dalbavancin in the treatment of different gram-positive infections: a real-life experience.
    Bouza E; Valerio M; Soriano A; Morata L; Carus EG; Rodríguez-González C; Hidalgo-Tenorio MC; Plata A; Muñoz P; Vena A;
    Int J Antimicrob Agents; 2018 Apr; 51(4):571-577. PubMed ID: 29180276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection.
    Tobudic S; Forstner C; Burgmann H; Lagler H; Steininger C; Traby L; Vossen MG; Winkler S; Thalhammer F
    Infection; 2019 Dec; 47(6):1013-1020. PubMed ID: 31520397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proactive therapeutic monitoring of dalbavancin concentrations in the long-term management of chronic osteoarticular/periprosthetic joint infections.
    Cattaneo D; Fusi M; Galli L; Genovese C; Giorgi R; Matone M; Merli S; Colaneri M; Gori A
    Antimicrob Agents Chemother; 2024 Apr; 68(4):e0002324. PubMed ID: 38385700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dalbavancin treatment of prosthetic knee infection due to oxacillin-resistant Staphylococcus epidermidis.
    Ramírez Hidalgo M; Jover-Sáenz A; García-González M; Barcenilla-Gaite F
    Enferm Infecc Microbiol Clin (Engl Ed); 2018 Feb; 36(2):142-143. PubMed ID: 28600171
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-Term Suppressive Therapeutic-Drug-Monitoring-Guided Dalbavancin Therapy for Cardiovascular Prosthetic Infections.
    Gallerani A; Gatti M; Bedini A; Casolari S; Orlando G; Puzzolante C; Franceschini E; Menozzi M; Santoro A; Barp N; Volpi S; Soffritti A; Pea F; Mussini C; Meschiari M
    Antibiotics (Basel); 2023 Nov; 12(11):. PubMed ID: 37998841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dalbavancin combined with linezolid in prosthetic-hip infection.
    Carrión Madroñal IM; Sánchez Del Moral R; Abad Zamora JM; Martínez Marcos FJ
    Rev Esp Quimioter; 2020 Apr; 33(2):147-148. PubMed ID: 32157859
    [No Abstract]   [Full Text] [Related]  

  • 10. Dalbavancin Efficacy and Impact on Hospital Length-of-Stay and Treatment Costs in Different Gram-Positive Bacterial Infections.
    Poliseno M; Bavaro DF; Brindicci G; Luzzi G; Carretta DM; Spinarelli A; Messina R; Miolla MP; Achille TI; Dibartolomeo MR; Dell'Aera M; Saracino A; Angarano G; Favale S; D'Agostino C; Moretti B; Signorelli F; Taglietti C; Carbonara S
    Clin Drug Investig; 2021 May; 41(5):437-448. PubMed ID: 33884583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter clinical experience of real life Dalbavancin use in gram-positive infections.
    Wunsch S; Krause R; Valentin T; Prattes J; Janata O; Lenger A; Bellmann-Weiler R; Weiss G; Zollner-Schwetz I
    Int J Infect Dis; 2019 Apr; 81():210-214. PubMed ID: 30794940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. French national cohort of first use of dalbavancin: A high proportion of off-label use.
    Dinh A; Duran C; Pavese P; Khatchatourian L; Monnin B; Bleibtreu A; Denis E; Etienne C; Rouanes N; Mahieu R; Bouchand F; Davido B; Lotte R; Cabaret P; Camou F; Chavanet P; Assi A; Limonta S; Lechiche C; Riou R; Courjon J; Illes G; Lacassin-Beller F; Senneville E;
    Int J Antimicrob Agents; 2019 Nov; 54(5):668-672. PubMed ID: 31400471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prolonged treatment with dalbavancin in prosthetic hip infection by methicillin-resistant Staphylococcus epidermidis].
    Trujillano Ruiz A; Mesquida Riera J; Serrano Fabiá MA; Riera Pérez E; Mejía Benard A; Taberner Ferrer MD
    Rev Esp Quimioter; 2019 Apr; 32(2):203-204. PubMed ID: 30868837
    [No Abstract]   [Full Text] [Related]  

  • 14. Dalbavancin as long-term suppressive therapy for patients with Gram-positive bacteremia due to an intravascular source-a series of four cases.
    Hitzenbichler F; Mohr A; Camboni D; Simon M; Salzberger B; Hanses F
    Infection; 2021 Feb; 49(1):181-186. PubMed ID: 32965641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Drug Monitoring of Dalbavancin Treatment in Severe Necrotizing Fasciitis in 3 Critically Ill Patients: A Grand Round.
    Corona A; Agarossi A; Veronese A; Cattaneo D; D'Avolio A
    Ther Drug Monit; 2020 Apr; 42(2):165-168. PubMed ID: 32195987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dalbavancin as suppressive antibiotic therapy in patients with prosthetic infections: efficacy and safety.
    Ruiz-Sancho A; Núñez-Núñez M; Castelo-Corral L; Martínez-Marcos FJ; Lois-Martínez N; Abdul-Aziz MH; Vinuesa-García D
    Front Pharmacol; 2023; 14():1185602. PubMed ID: 37448966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current trends in the real-life use of dalbavancin: report of a study panel.
    Durante-Mangoni E; Gambardella M; Iula VD; De Stefano GF; Corrado MF; Esposito V; Gentile I; Coppola N
    Int J Antimicrob Agents; 2020 Oct; 56(4):106107. PubMed ID: 32721599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Head-to-head comparison of multi-dose oritavancin and dalbavancin for complicated infections: A propensity score-matched analysis.
    Steuber TD; Gipson H; Boyett B; Belk M; Thayer B; Edwards J
    Int J Antimicrob Agents; 2024 Jun; 63(6):107165. PubMed ID: 38570019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience with dalbavancin for the treatment of deep sternal wound infection.
    Bartoletti M; Mikus E; Pascale R; Giannella M; Tedeschi S; Calvi S; Tenti E; Tumietto F; Viale P
    J Glob Antimicrob Resist; 2019 Sep; 18():195-198. PubMed ID: 30926464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with dalbavancin in a patient with septic thrombophlebitis of the internal jugular vein due to Staphylococcus aureus after insertion of an implantable cardioverter defibrillator.
    Martínez-Sanz J; Gijón de la Santa L; Torralba M
    Enferm Infecc Microbiol Clin (Engl Ed); 2018; 36(6):389-390. PubMed ID: 29132942
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.